Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • AL-335: Phase I started

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: AL-335 Business: Infectious Molecular target: HCV NS5B polymerase Description: Uridine-based nucleotide analog inhibitor of HCV NS5B polymerase Indication: …

    Published on 8/10/2015
  • ALLN-177: Phase IIb started

    Allena Pharmaceuticals Inc., Newton, Mass. Product: ALLN-177 Business: Endocrine/Metabolic Molecular target: NA Description: Oral recombinant oxalate degrading enzyme Indication: Treat secondary hyperoxaluria and …

    Published on 8/10/2015
  • ALX-0061: Phase II started

    Ablynx N.V. (Euronext:ABLX), Ghent, Belgium AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: ALX-0061 (formerly subcutaneous ALX-0061, SC ALX-0061) Business: Autoimmune Molecular target: Interleukin-6 (IL-6) receptor (…

    Published on 8/10/2015
  • APX005M: Phase I started

    Apexigen Inc., San Carlos, Calif. Product: APX005M Business: Cancer Molecular target: CD40 Description: Agonistic humanized mAb that targets CD40 Indication: Treat solid tumors Endpoint: Maximum tolerated dose (MTD) and…

    Published on 8/10/2015
  • Brentuximab vedotin: Phase II started

    Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Brentuximab vedotin (Adcetris) (SGN-35) Business: Autoimmune Molecular target: CD30 Description: …

    Published on 8/10/2015
  • Brincidofovir: Completed Phase III enrollment

    Chimerix Inc. (NASDAQ:CMRX), Durham, N.C. Product: Brincidofovir (CMX001) Business: Infectious Molecular target: NA Description: Oral lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations …

    Published on 8/10/2015
  • CRS-207: Phase IIb ongoing

    Aduro Biotech Inc. (NASDAQ:ADRO), Berkeley, Calif. Product: CRS-207 Business: Cancer Molecular target: NA Description: Live attenuated strain of Listeria monocytogenes that expresses human mesothelin Indication: Treat …

    Published on 8/10/2015
  • DRM04: Phase III started

    Dermira Inc. (NASDAQ:DERM), Menlo Park, Calif. Product: DRM04 Business: Other Molecular target: NA Description: Topical anticholinergic agent Indication: Treat primary axillary hyperhidrosis Endpoint: Average absolute …

    Published on 8/10/2015
  • ELI-200: Completed Phase III enrollment

    Elite Pharmaceuticals Inc. (OTCQB:ELTP), Northvale, N.J. Product: ELI-200 Business: Neurology Molecular target: Opioid receptor (OPR) Description: Abuse deterrent-formulation of oxycodone and naltrexone Indication: …

    Published on 8/10/2015
  • FPA008: Phase I/II started

    Five Prime Therapeutics Inc. (NASDAQ:FPRX), South San Francisco, Calif. Product: FPA008 Business: Inflammation Molecular target: Colony-stimulating factor 1 receptor (CSF1R) (C-FMS) (CD115) Description: Humanized mAb …

    Published on 8/10/2015
  • Graspa: Phase I ongoing

    Erytech Pharma S.A. (Euronext:ERYP), Lyon, France Product: Graspa, ERY-ASP (ERY001) Business: Cancer Molecular target: NA Description: L-asparaginase encapsulated in red blood cells Indication: Treat acute lymphoblastic…

    Published on 8/10/2015
  • Graspa: Phase II ongoing

    Erytech Pharma S.A. (Euronext:ERYP), Lyon, France Product: Graspa, ERY-ASP (ERY001) Business: Cancer Molecular target: NA Description: L-asparaginase encapsulated in red blood cells Indication: Second-line treatment of …

    Published on 8/10/2015
  • GVAX Pancreas cancer vaccine: Phase IIb ongoing

    Aduro Biotech Inc. (NASDAQ:ADRO), Berkeley, Calif. Product: GVAX Pancreas cancer vaccine Business: Cancer Molecular target: NA Description: Allogeneic cancer vaccine engineered to secrete GM-CSF Indication: Treat …

    Published on 8/10/2015
  • HLD-200: Phase III started

    Highland Therapeutics Inc., Toronto, Ontario Product: HLD-200 Business: Neurology Molecular target: Dopamine transporter; Norepinephrine transporter Description: Modified-release formulation of the generic …

    Published on 8/10/2015
  • HTX-011: Phase II started

    Heron Therapeutics Inc. (NASDAQ:HRTX), Redwood City, Calif. Product: HTX-011 Business: Neurology Molecular target: Sodium channel voltage-dependent; Cyclooxygenases (COX) Description: Long-acting formulation of the …

    Published on 8/10/2015
  • oral MGB-BP-3: Phase I started

    MGB Biopharma Ltd., Glasgow, U.K. Product: oral MGB-BP-3 Business: Infectious Molecular target: NA Description: Oral antibiotic that binds the minor groove of bacterial DNA Indication: Treat Clostridium difficile …

    Published on 8/10/2015
  • Patisiran: Extension study started

    Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Patisiran (GZ438027, GENZ438027, ALN-TTR02) Business: Endocrine/Metabolic Molecular target: …

    Published on 8/10/2015
  • QuickShot Testosterone: Phase III started

    Antares Pharma Inc. (NASDAQ:ATRS), Ewing, N.J. Product: QuickShot Testosterone, QS T Business: Endocrine/Metabolic Molecular target: Androgen receptor Description: Self-injectable formulation of testosterone enanthate …

    Published on 8/10/2015
  • Resminostat: Phase I started

    4SC AG (Xetra:VSC), Planegg-Martinsried, Germany Yakult Honsha Co. Ltd. (Tokyo:2267), Tokyo, Japan Product: Resminostat (4SC-201) (formerly BYK408740) Business: Cancer Molecular target: Histone deacetylase (HDAC) …

    Published on 8/10/2015
  • RhGUS: Phase II started

    Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Novato, Calif. Product: RhGUS (UX003) Business: Endocrine/Metabolic Molecular target: NA Description: Recombinant human glucuronidase beta (rhGUS) Indication: Treat …

    Published on 8/10/2015
  • Rilimogene galvacirepvec: Phase II started

    Bavarian Nordic A/S (CSE:BAVA), Kvistgaard, Denmark Product: Rilimogene galvacirepvec (ProstVac) Business: Cancer Molecular target: Prostate-specific antigen (KLK3) (PSA) Description: Vaccine targeting PSA that also …

    Published on 8/10/2015
  • Selumetinib: Development discontinued

    Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Selumetinib (ARRY-886, AZD6244) Business: Cancer Molecular target: MEK Description: Small molecule MEK …

    Published on 8/10/2015
  • Adenovirus expressing melanoma-associated antigen A3: Phase I/IIa started

    Turnstone Biologics Inc., Toronto, Ontario Product: Adenovirus expressing melanoma-associated antigen A3 (MAGEA3)/MG1 Maraba virus expressing MAGEA3 Business: Cancer Molecular target: NA Description: Adenovirus …

    Published on 8/3/2015
  • ALN-AAT: Phase I/II started

    Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Product: ALN-AAT Business: Hepatic Molecular target: Alpha-1 antitrypsin (AAT) (A1AT) (SERPINA1) Description: Short interfering RNA (siRNA) targeting alpha-1 …

    Published on 8/3/2015
  • AuriPro: Phase II started

    Otonomy Inc. (NASDAQ:OTIC), San Diego, Calif. Product: AuriPro (formerly OTO-201) Business: Infectious Molecular target: DNA gyrase Description: Sustained-release gel formulation of ciprofloxacin Indication: Treat acute…

    Published on 8/3/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993